Speciality: Infectious diseases
Description:
A warm welcome to all the medical professionals in this interesting learning session on bridging the gap between AMR surveillance and antibiotic policy for appropriate therapy.
In this webinar, a panel discussion would take place involving Dr Subramanian Swaminathan as the primary speaker and involving other panelists to participate and discuss the important facts associated with antibiotic resistance and the policies to be adapted for introducing an appropriate therapy.
Antimicrobial surveillance is an essential pillar in fighting against antimicrobial resistance (AMR). There is a lack of understanding and practical guidance on how surveillance data should be linked to AMS activities. Moreover, it becomes much more complex in the hospital setting because of the structural heterogeneity of hospital facilities and services.
Therefore, the webinar will give you an overall guidance on bridging the gap between AMR surveillance and antibiotic policy for appropriate therapy. Listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions
See More Webinars @ Hidoc Webinars
1.
Beyond What Is Visible in Myelofibrosis?
2.
FDA approves rivanetin as the first-line treatment for lung cancer.
3.
In high-risk muscle invasive urothelial cancer, adjuvant pembrolizumab improves disease-free survival.
4.
New First-Line Option for Advanced ALK-Positive Lung Cancer
5.
Certain surgical gestures during prostate removal linked to better sexual function recovery
1.
Tremelimumab: A Potential Breakthrough in Cancer Treatment
2.
The Technological Revolution in Precision Oncology and Tumor Microenvironment Therapy
3.
Artificial Intelligence for Early Cancer Detection Leveraging Multi-Omics: A Comprehensive Review
4.
Harnessing Snake Venom in Hematology: From Toxins to Life-Saving Therapeutics
5.
Unlocking the Potential of SCD: A Comprehensive Guide to Diagnosis and Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII
2.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
3.
Updates on Standard V/S High Risk Myeloma Treatment
4.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V
5.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation